Robert M. Janosky
Corporate Officer/Principal presso SATSUMA PHARMACEUTICALS, INC.
Profilo
Robert M.
Janosky is currently the Chief Commercial Officer at Satsuma Pharmaceuticals, Inc. Prior to this, he worked as the VP of Business Development & Strategic Planning at DURECT Corp.
from 2016 to 2020.
He received his undergraduate degree from the University of Vermont and his MBA from the University of Rochester Simon Business School.
Posizioni attive di Robert M. Janosky
| Società | Posizione | Inizio |
|---|---|---|
| SATSUMA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 05/03/2020 |
Precedenti posizioni note di Robert M. Janosky
| Società | Posizione | Fine |
|---|---|---|
| DURECT CORPORATION | Corporate Officer/Principal | 01/03/2020 |
Formazione di Robert M. Janosky
| University of Vermont | Undergraduate Degree |
| University of Rochester Simon Business School | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| DURECT CORPORATION | Health Technology |
| Aziende private | 1 |
|---|---|
Satsuma Pharmaceuticals, Inc.
 Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
- Borsa valori
- Insiders
- Robert M. Janosky
